FrancophonIA/ELRC3.0 huggingface dataset:
English: Docetaxel Zentiva can only be obtained with a prescription and is used in units specialising in giving chemotherapy (medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Estonian: Docetaxel Zentiva on retseptiravim ja seda kasutatakse keemiaravile (vähi ravimravi) spetsialiseerunud osakonnas keemiaravi kasutamises pädeva arsti järelevalve all.
English: For the full list of side effects with Docetaxel Zentiva, see the package leaflet.
Estonian: Docetaxel Zentiva kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The dose of Docetaxel Zentiva may need to be reduced, or treatment interrupted or discontinued, if the patient develops certain side effects.
Estonian: Kui patsiendil tekivad teatavad kõrvalnähud, võib olla vaja Docetaxel Zentiva annust vähendada või ravi katkestada või lõpetada.
English: The active substance in Docetaxel Zentiva, docetaxel, belongs to the group of cancer medicines known as taxanes.
Estonian: Docetaxel Zentiva toimeaine dotsetakseel kuulub vähiravimite taksaanide rühma.
English: How is Docetaxel Zentiva used?
Estonian: Kuidas Docetaxel Zentivat kasutatakse?
English: An overview of Docetaxel Zentiva and why it is authorised in the EU
Estonian: Ülevaade ravimist Docetaxel Zentiva ja ELis müügiloa väljastamise põhjendus
English: How does Docetaxel Zentiva work?
Estonian: Kuidas Docetaxel Zentiva toimib?
English: What benefits of Docetaxel Zentiva have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Docetaxel Zentiva kasulikkus?
English: These side effects may be more severe when Docetaxel Zentiva is used with other cancer medicines.
Estonian: Kui Docetaxel Zentivat kasutatakse muude vähiravimitega, võivad need kõrvalnähud olla raskemad.
English: • head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
Estonian: • Pea- ja kaelapiirkonna lokaalselt kaugelearenenud (metastaasideta) vähk.
English: 12 February 2013
Estonian: 12. veebruar 2013
English: The final opinion was converted into a Decision by the European Commission on 12 February 2013.
Estonian: Lõplik arvamus vormistati Euroopa Komisjoni otsusena 12. veebruaril 2013. aastal.
English: The decentralised procedure (NL/V/0164/003/DC) started on 17 June 2011.
Estonian: Detsentraliseeritud menetlus (NL/V/0164/003/DC) algas 17. juunil 2011.
English: International non-proprietary name (INN): meloxicam
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): meloksikaam
English: Written explanations were provided by the applicant on 11 September 2012.
Estonian: Taotleja esitas kirjalikud selgitused 11. septembril 2012.
English: The referral procedure started on 11 July 2012.
Estonian: Esildismenetlus algas 11. juulil 2012.
English: Veterinary Medicines and Product Data Management
Estonian: Veterinaarravimid ja ravimteabe haldus
English: The application was submitted to the Netherlands as reference Member State and Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Italy, Poland, Spain and the United Kingdom as concerned Member States.
Estonian: Viiteliikmesriik oli Madalmaad ning asjaomased liikmesriigid olid Austria, Belgia, Hispaania, Iirimaa, Itaalia, Poola, Prantsusmaa, Saksamaa, Taani, Tšehhi Vabariik, Ungari ja Ühendkuningriik.
English: The Committee appointed Ms H. Jukes as rapporteur and Mr G. J. Schefferlie as co-rapporteur.
Estonian: Veterinaarravimite komitee määras hindajaks H. Jukesi ja kaashindajaks G. J. Schefferlie.
English: Potential serious risks were identified during the decentralised procedure by two concerned Member States, Ireland and the United Kingdom, regarding the bioequivalence for the target species pigs.
Estonian: Detsentraliseeritud menetluse käigus tõstatasid kaks asjaomast liikmesriiki - Iirimaa ja Ühendkuningriik - küsimuse võimalikest tõsistest riskidest seoses ravimi bioekvivalentsusega sihtloomaliigil sigadel.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amendments to the Summary of Product Characteristics, labelling and package leaflet in the Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning ravimi omaduste kokkuvõtte, pakendi märgistuse ja infolehe muudatused III lisas.
English: The active substance is included in veterinary medicinal products currently authorised in the European Union via the centralised authorisation procedure, as well as nationally, for use in cattle, pigs, horses, dogs and cats.
Estonian: Toimeaine sisaldub veterinaarravimites, millel on praegu Euroopa Liidus riikides tsentraliseeritud või riikliku menetlusega antud müügiluba kasutamiseks veistel, sigadel, hobustel, koertel ja kassidel.
English: Based on the evaluation of the currently available data, the CVMP considered that the particulars concerning the target species pigs that were submitted in support of the application do not comply with Article 13 of Directive 2001/82/EC, and consequently do not satisfy the criteria for authorisation in respect of safety and efficacy for the target species pigs.
Estonian: Olemasolevate andmete hindamisel leidis veterinaarravimite komitee, et taotluse toetamiseks esitatud üksikasjad seoses sihtloomaliigi sigadega ei vasta direktiivi 2001/82/EÜ artiklile 13 ega rahulda seega müügiloa andmise kriteeriume seoses ohutuse ja efektiivsusega sihtloomaliigil sigadel.
English: On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 2 May 2012.
Estonian: Need küsimused olid 210. päeval ikka veel lahenduseta ning seetõttu tehti 2. mail 2012 veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühmale direktiivi 2001/82/EÜ artikli 33 lõike 1 kohane esildis.
English: This is a ‘hybrid' application according to Article 13(3) Directive 2001/82/EC, as amended, referring to the centrally authorised reference product Metacam 20 mg/ml solution for injection for cattle, pigs and horses (EU/2/97/004).
Estonian: See on muudetud direktiivi 2001/82/EÜ artikli 13 lõike 3 kohane hübriidtaotlus, milles on viidatud tsentraalse müügiloaga võrdlusravimile Metacam 20 mg/ml, mis on veiste, sigade ja hobuste süstelahus (EU/2/97/004).
English: The applicant, CP-Pharma Handelsgesellschaft mbH, submitted an application for a decentralised procedure for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses.
Estonian: Taotleja CP-Pharma Handelsgesellschaft mbH esitas detsentraliseeritud menetluse taotluse Mesolute 40 mg/ml süstelahuse kasutamiseks veiste, sigade ja hobuste ravis.
English: Therefore, the Committee adopted a negative opinion on 8 November 2012 recommending the refusal of the granting of the marketing authorisation for Melosolute 40 mg/ml solution for injection for the target species pigs.
Estonian: Seetõttu võttis veterinaarravimite komitee 8. novembril 2012 vastu negatiivse arvamuse, milles ta soovitas keelduda andmast müügiluba sihtloomaliigile sigadele ette nähtud süstelahusele Melosolute 40 mg/ml.
English: On 29 June 2012 the reference Member State, the Netherlands, notified to the European Medicines Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC.
Estonian: 29. juunil 2012 teatas viiteliikmesriik Madalmaad Euroopa Ravimiametile, et veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühm ei saavutanud ravimi suhtes kokkulepet, ning suunas direktiivi 2001/82/EÜ artikli 33 lõike 4 alusel küsimuse edasi veterinaarravimite komiteele.
English: Melosolute 40 mg/ml solution for injection for cattle, pigs and horses contains meloxicam as active ingredient.
Estonian: Melosolute 40 mg/ml süstelahus veistele, sigadele ja hobustele sisaldab toimeainena meloksikaami.
English: Meloxicam is a Non-Steroidal Anti-Inflammatory Drug.
Estonian: Meloksikaam on mittesteroidne põletikuvastane ravim.
English: Day 60 of the CMD(v) procedure was on 29 June 2012, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP.
Estonian: Veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühma menetluse 60. päev oli 29. juuni 2012 ja et asjaomased liikmesriigid ei jõudnud ravimi osas kokkuleppele, suunati menetlus edasi veterinaarravimite komiteele.
English: Opinion following an Article 33(4)0F referral for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses
Estonian: Arvamus pärast artikli 33 lõike 40F kohast esildist Mesolute 40 mg/ml süstelahus veistele, sigadele ja hobustele
English: referral for Melosolute 40 mg/ml solution for injection for cattle, pigs and horses
Estonian: Arvamus pärast artikli 33 lõike 41 kohast esildist Mesolute 40 mg/ml süstelahus veistele, sigadele ja hobustele
English: Alar Irs (Estonia)
Estonian: Alar Irs (Eesti)
English: Outcome of a procedure under Article 30 of Directive 2001/83/EC
Estonian: Direktiivi 2001/83/EÜ artikli 30 kohase esildismenetluse tulem
English: The amended information to doctors and patients is available here.
Estonian: atud teave arstidele ja patsientidele on siin
English: Pieter de Graeff (The Netherlands)
Estonian: Pieter de Graeff (Madalmaad)
English: What is Atacand Plus?
Estonian: Mis on Atacand Plus?
English: The companies that market these medicines are AstraZeneca and Takeda.
Estonian: Ravimeid turustavad AstraZeneca and Takeda.
English: Atacand Plus is authorised in the EU via national procedures.
Estonian: Atacand Plus kiideti Euroopa Liidus heaks riiklike menetluste kaudu.
English: Other changes
Estonian: used
English: Why was Atacand Plus reviewed?
Estonian: Miks Atacand Plusi taotlus uuesti läbi vaadati?
English: Atacand Plus should be taken at a dose of one tablet once a day.
Estonian: Atacand Plusi tuleb võtta üks tablett üks kord ööpäevas.
English: Atacand Plus is also available in the EU under other trade names: Atacand Plus Forte, Atacand Plus Mite, Atacand Zid, Blopresid, Blopress, Blopress Comp, Blopress Forte, Blopress Plus, CoKenzen, Hytacand, Parapres Comp, Parapres Comp Forte, Parapres Plus and Ratacand Plus.
Estonian: Atacand Plus Mite, Atacand Zid, Blopresid, Blopress, Blopress Comp, Blopress Forte, Blopress Plus, CoKenzen, Hytacand, Parapres Comp, Parapres Comp Forte, Parapres Plus ja Ratacand Plus.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Sel põhjusel ei ühti eri liikmesriikides ravimi kasutamisvõimalused, nagu nähtub erinevustest ravimi omaduste kokkuvõtetes, pakendi märgistustes ja pakendi infolehtedes riikides, kus neid ravimeid turustatakse.
English: EMA/CHMP/402912/2010 rev.1 EMEA/H/A-30/001152
Estonian: EMEA/H/A-30/001152
English: It works by increasing urine output, reducing the amount of fluid in the blood and reducing blood pressure.
Estonian: See suurendab uriinieritust ning vähendab vedeliku hulka veres, mille tulemusena vererõhk alaneb.
English: Referral start date:
Estonian: Esildismenetluse alustamise kuupäev:
English: The European Medicines Agency has completed a review of Atacand Plus and associated names.
Estonian: EMA) on lõpetanud Atacand Plusi ja sarnaste nimetuste kohta tehtud taotluse läbivaatamise.
English: This means that the doctor should try different tablet strengths until the strength that adequately controls the patient's blood pressure is found.
Estonian: Annust on soovitatav tii et arst katsetab eri tugevusega tablette, kuni leitakse annus, mis reguleerib patsiendi vajalikul määral.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Estonian: ndamise ja komitees toimunud teadusliku arutelu põhjal jõudis inimravimite te kokkuvõtted, märgistused ja pakendi infolehed tuleb Euroopa ada.
English: Candesartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Kandesartaan on angiotensiin II retseptori antagonist, mis blokeerib organismis h angiotensiin II toime.
English: The CHMP recommended that Atacand Plus be used to treat essential hypertension in adults whose blood pressure is not optimally controlled by candesartan cilexetil or hydrochlorothiazide alone.
Estonian: Inimravimite komitee soovit täiskasvanutel, kelle vererõhku ei saa optimaalselt reguleerida ainult kandesartaa hüdroklorotiasiidiga.
English: It must also not be given to women in their second or third trimesters of pregnancy or to patients with severe kidney or liver problems, cholestasis (problems with the elimination of bile), gout (a painful inflammation of the joints) and hypokalaemia (low blood potassium levels) or hypercalcaemia (high blood calcium levels).
Estonian: Atacand Plusi ei tohi a teisel ja kolmandal trimestril ega ka raske podagra (valulik liigesepõletik), hüpokale (vere suur kaltsiumisisaldus) patsientidel ud lõigud, sealhulgas erihoiatuste, koostoime imitega ning rased mise lõigud.
English: On 27 October 2009, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Atacand Plus in the EU.
Estonian: 27. oktoobri komiteele esildise, et ühtlustada Atacand Plu
English: The European Commission issued a decision on 16 September 2010.
Estonian: Euroopa Komis se 16. septem
English: Company responses provided on: 25 February 2010 Opinion date:
Estonian: Ettevõtte vastuste kuupäev:
English: Atacand Plus is a medicine that contains two active substances candesartan cilexetil and hydrochlorothiazide.
Estonian: Atacand Plus on ravim, mis sisaldab kahte toim Seda kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) raviks.
English: By blocking the receptors to which angiotensin II normally attaches, candesartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to fall.
Estonian: Angiotensiin II on tugev vasokonstriktor (veresooni ahend retseptorid, millega angiotensiin II tavaliselt seondub, peatab kandesartaa soodustab veresoonte laienemist, nii et
English: The Committee also harmonised other sections of the SmPC including sections on special warnings, interactions with other medicines and pregnancy and lactation.
Estonian: Komitee ühtlustas ka ravimi omaduste kokkuvõtte mu teiste rav use ja imeta
English: ‘Essential' means that the hypertension has no obvious cause.
Estonian: Essents kõrgvererõhutõbe ei põhjusta ükski teine haigus.
English: Atacand Plus was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluse koordine Atacand Plusi ühtlustamist vajavaks ravimiks.
English: Atacand Plus must not be used in patients who are hypersensitive (allergic) to the active substances, any of the other ingredients or to substances derived from sulfonamide.
Estonian: Atacand Plusi ei tohi kasutada patsiendid, kes on toimeainete, ravimi mis tahes muu koostisaine või nda naistele raseduse kujulise neeru- või maksaprobleemi, kolestaasi (sapipais), emia (vere väike kaaliumisisaldus) või hüperkaltseemiaga e.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Atacand Plus in the European Union (EU).
Estonian: Esitatud andmete hi komitee järeldusele, et ravimi omadus Liidus ühtlust
English: 4.2 Posology and method of administration
Estonian: 4.2 Annustamine trida.
English: The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone.
Estonian: Hüdroklorotiasiid on diureetikum, mis on hüpertens kombinatsioonil on aditiivne toime: kombinatsioon alandab vererõhku roh
English: FI-02200 Espoo FINLAND
Estonian: FI-02200 Espoo SOOME
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 13/04/2018
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 13/04/2018
English: pH 3.8-4.5 and osmolality 300-400 mOsm/kg.
Estonian: pH 3,8-4,5 ja osmolaalsus 300-400 mOsm/kg.
English: It is recommended to record the time of first administration.
Estonian: Soovitatav on esimese manustamiskorra aeg üles märkida.
English: Ask your veterinarian or pharmacist how to dispose of medicines no longer required.
Estonian: Küsige oma loomaarstilt või apteekrilt, kuidas hävitatakse ravimeid, mida enam ei vajata.
English: Pharmacotherapeutic group: Dopaminergic agents, dopamine agonists ATC vet code: QN04BC04
Estonian: Farmakoterapeutiline rühm: dopaminergilised ained, dopamiini agonistid ATCvet kood: QN04BC04
English: If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinarian.
Estonian: Kui täheldate ükskõik milliseid kõrvaltoimeid, isegi neid, mida pole käesolevas pakendi infolehes mainitud, või arvate, et veterinaarravim ei toimi, teavitage sellest oma veterinaararsti.
English: Three dogs (3%) did not vomit at all despite an additional dose.
Estonian: Kolm koera (3%) ei oksendanud üldse lisaannuse manustamisest hoolimata.
English: See the detailed instructions for administration at the end of this leaflet.
Estonian: Üksikasjalikud manustamisjuhised leiate selle infolehe lõpust.
English: The fraction bound to plasma proteins in dogs is low (37%).
Estonian: Plasmavalkudega seonduv fraktsioon on koertel madal (37%).
English: Extended vomiting (for more than 60 minutes) which should be evaluated by the responsible veterinarian as it might need appropriate treatment.
Estonian: Pikaajalist (rohkem kui 60 minutit) oksendamist hindab vastutav loomaarst, kuna see võib vajada asjakohast ravi.
English: Within 30 minutes 95% of the dogs vomited.
Estonian: 30 minuti jooksul oksendas 95% koertest.
English: Ropinirole is rapidly distributed and has a relatively high apparent volume of distribution.
Estonian: Ropinirool jaotub kiiresti ja selle näiv jaotusruumala on suhteliselt suur.
English: Each eye drop contains 810 µg of ropinirole.
Estonian: Iga silmatilk sisaldab 810 µg ropinirooli.
English: The volume of one drop is approximately 27 µl.
Estonian: Ühe tilga ligikaudne kogus on 27 µl.
English: The efficacy of the veterinary medicinal product has not been established in dogs weighing less than 1.8 kg, or in dogs under 4.5 months of age or in elderly dogs.
Estonian: Veterinaarravimi tõhusus ei ole piisavalt tõestatud vähem kui 1,8 kg kaaluvatel, alla 4,5 kuu vanustel ega eakatel koertel.
English: Based on the clinical trial results, most dogs are expected to respond to a single dose of the veterinary medicinal product; however, a small proportion of dogs will require a second dose to induce vomiting.
Estonian: Kliiniliste uuringute tulemuste põhjal võib eeldada, et enamik koeri reageerib veterinaarravimi üksikannusele, kuid vähesed koerad vajavad oksendamise esilekutsumiseks ka teist annust.
English: Pack sizes: 1, 2, 3, 4, 5, 6, 8 and 10 single-dose containers.
Estonian: Pakendi suurused: 1, 2, 3, 4, 5, 6, 8 ja 10 üheannuselist konteinerit.
English: The systemic bioavailability of the drug by this ocular route of administration is 23%.
Estonian: Okulaarselt manustatava ravimi süsteemne biosaadavus on 23%.
English: 1 x 0.6 ml single-dose container 2 x 0.6 ml single-dose containers 3 x 0.6 ml single-dose containers 4 x 0.6 ml single-dose containers 5 x 0.6 ml single-dose containers 6 x 0.6 ml single-dose containers 8 x 0.6 ml single-dose containers 10 x 0.6 ml single-dose containers
Estonian: 1 × 0,6 ml üheannuseline konteiner 2 × 0,6 ml üheannuselist konteinerit 3 × 0,6 ml üheannuselist konteinerit 4 × 0,6 ml üheannuselist konteinerit 5 × 0,6 ml üheannuselist konteinerit 6 × 0,6 ml üheannuselist konteinerit 8 × 0,6 ml üheannuselist konteinerit 10 × 0,6 ml üheannuselist konteinerit
English: This veterinary medicinal product does not require any special temperature storage conditions.
Estonian: Veterinaarravim ei vaja säilitamisel temperatuuri eritingimusi.
English: The veterinary medicinal product should not be administered by pregnant or breast-feeding women.
Estonian: Veterinaarravimit ei tohi manustada rasedad ega rinnaga toitvad naised.
English: In case of accidental eye or skin contact, rinse immediately the affected area with plenty of fresh water.
Estonian: Juhuslikul silma või nahale sattumisel loputada vastavat piirkonda rohke puhta veega.
English: In dogs, the volume of distribution (Vz) is 5.6 l/kg after intravenous administration.
Estonian: Koerte puhul on jaotusruumala (Vz) pärast intravenoosset manustamist 5,6 l/kg.
English: The time between the first to the last vomit was 0-108 minutes (0 if the dog vomited only once) with a mean duration of 23 minutes and a median duration of 16 minutes.
Estonian: Aeg esimese ja viimase oksendamiskorra vahel oli 0-108 minutit (0, kui koer oksendas vaid korra), keskmine oksendamise kestus oli 23 minutit ja mediaanne kestus 16 minutit.
English: Increased mean heart rate was observed one hour after treatment with all three doses (1X, 3X, 5X) and went back to normal levels after 6 hours.
Estonian: Kiirenenud keskmist pulssi täheldati ravimi manustamisest ühe tunni möödumisel kõigi kolme annuse (1X, 3X, 5X) korral ja pulsi normaalsagedus taastus kuue tunni järel.
English: Very slightly yellow to yellow clear solution.
Estonian: Helekollane kuni kollane läbipaistev lahus.
English: If symptoms occur, seek medical advice and show the package leaflet or the label to the physician.
Estonian: Sümptomite tekkimisel pöörduda arsti poole ja näidata pakendi infolehte või pakendi etiketti.
English: Symptoms of overdose consist of the same signs seen as adverse reactions.
Estonian: Üleannustamise sümptomid sarnanevad kõrvaltoimete korral täheldatud nähtudega.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Estonian: TEKSTI LÄBIVAATAMISE KUUPÄEV Üksikasjalikku teavet selle veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt (http://www.ema.europa.eu/).
English: A very small proportion of dogs may fail to respond to the treatment despite administration of a second dose.
Estonian: Väga väikesel osal koertel ei pruugi ravivastus avalduda teise annuse manustamisest hoolimata.
English: The pouches are further packed in outer cardboard cartons which contain 1, 2, 3, 4, 5, 6, 8 or 10 single-dose containers, together with the corresponding number of package leaflets.
Estonian: Ümbrised on seejärel pakitud välistesse kartongkarpidesse, mis sisaldavad 1, 2, 3, 4, 5, 6, 8 või 10 üheannuselist konteinerit, koos vastava arvu pakendi infolehtedega.
English: Ropinirole is a full dopamine agonist with high selectivity for the dopamine D2-like receptor family (D2, D3 and D4 receptors).
Estonian: Ropinirool on täielik dopamiini agonist, millel on suur selektiivsus D2-tüüpi retseptorite (D2, D3-ja D4 retseptorite) suhtes.
English: The pouch/pouches are then packed in a cardboard box together with the same number of package leaflets (intended for the animal owners) as the number of single-dose containers in the outer package.
Estonian: Ümbris/ümbrised on pakitud kartongkarpi, kuhu on lisatud sama arv pakendi infolehti (mõeldud loomaomanikele), kui on üheannuselisi konteinereid välispakendis.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label or carton after “EXP”.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud sildil või karbil pärast märget „Kõlblik kuni / EXP”.